Ovarian immature teratomas (IT) with microscopic yolk sac tumor (YST) occur in approximately 11% of cases in children and adolescents.
Patients with microscopic YST present with higher tumor grade, stage, and elevated alpha fetoprotein levels at diagnosis compared to IT without YST.
Despite adverse pathological features, recurrence-free survival (RFS) does not significantly differ between those with and without microscopic YST.
Treatment regimens often include chemotherapy for microscopic YST, which may impact recurrence outcomes, highlighting the need for standardized management guidelines.
